Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?

During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for ocrelizumab infusions in Relapsing Remitting Multiple Sclerosis (RRMS) patients according to the national recommendations. Out of the 83 RRMS patients whose infusion was scheduled between March and December 2020, 56 patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurol Sci
Main Authors: Tazza, F., Lapucci, C., Cellerino, M., Boffa, G., Novi, G., Poire, I., Mancuso, E., Bruschi, N., Sbragia, E., Laroni, A., Capello, E., Inglese, M.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier B.V. 2021
Assuntos:
Clinical Short Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8133824/
https://ncbi.nlm.nih.gov/pubmed/34044238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jns.2021.117501
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados